Bond.az White LogoBond.az Black Logo

Morgan Stanley Reiterates Home Depot Rating on Execution

Morgan Stanley reiterates Overweight rating on Home Depot with $420 target, citing solid execution in a growthless housing market.

Luna Torres
ByLuna Torres- Senior Editor
|
0

Morgan Stanley reiterated an Overweight rating and $420 price target on Home Depot (NYSE:HD) after the company's Q1 fiscal 2026 results.

The firm notes Home Depot executes well in a growthless environment. The housing backdrop remains static. Shares trade at $299.81, near the 52-week low of $296.88. The stock is down 12% YTD and 19% over the past year.

Transactions are stable at a high level, possibly impacted by weather in April. The consensus mis-modeled Q1 gross margin, making the quarter complexion in line.

Morgan Stanley sees favorable risk/reward and likes HD as a high-quality discretionary play. The stock does not price in a housing recovery, trading at a 7% discount to the S&P 500 versus its historical 10-15% premium.

Estimates have bottomed; Q1 results do not change the 2026 EPS power view. Maintenance and repair demand should drive modest growth.

In other news, HD's Q1 results met revenue and earnings expectations. Comparable sales rose 0.6% enterprise-wide and 0.4% in the U.S. EBIT margin of 12.3% beat the Street estimate of 12.1%. Truist Securities and TD Cowen reiterated Buy ratings, while Stifel maintained Hold with a lowered price target from $375 to $320.

More News
Today / 12:31
|
212

Compass Point Lowers DeFi Tech Target

Compass Point cuts DeFi Technologies price target to $1.45, maintains Buy rating amid bear market.

0
Today / 12:30
|
656

Benchmark Reiterates Baidu Stock Rating on AI Revenue Milestone

Benchmark reaffirms Buy rating on Baidu after AI revenue milestone. AI Cloud margins improve, new products launched.

0
Today / 12:04
|
952

Raymond James Backs Nutrien Stock on Potash

Raymond James backs Nutrien stock with Outperform rating and $90 target after Indian potash deal. 26% upside, strong financials.

0
Today / 11:35
|
858

Mizuho Raises STM Price Target on AI Growth

Mizuho raises STMicroelectronics price target to $68, citing AI growth and new technologies.

0
Today / 11:03
|
967

Oppenheimer Reiterates Outperform on UroGen Pharma

Oppenheimer reiterates Outperform on UroGen Pharma with $40 target. Strong commercial momentum for Zusduri driven by physician enthusiasm.

0
Today / 11:02
|
510

Guggenheim Upgrades StubHub Stock on Reset

Guggenheim upgrades StubHub stock to Buy with a $12.50 price target, citing reset expectations and growth catalysts like the World Cup.

0
Today / 10:31
|
290

Wolfe Research Initiates CytomX Stock with Outperform

Wolfe Research initiated CytomX Therapeutics (CTMX) with an outperform rating and $3.50 target. Varseta-M shows promise in colorectal cancer.

0
Today / 10:30
|
842

Wolfe Research initiates Mirum with outperform

Wolfe Research starts Mirum Pharmaceuticals with outperform rating and $145 price target, citing strong pipeline potential.

0
Today / 10:14
|
236

Wolfe Research Initiates Oklo with Peerperform

Wolfe Research initiated Oklo Inc. with a Peerperform rating. Learn about the company's targets, finances, and stock performance.

0
Today / 10:13
|
631

Aletheia Capital Reaffirms Circle Stock Rating

Aletheia Capital reaffirms Buy rating on Circle Internet Group amid U.S. stablecoin regulatory advantages. Stock at $111.39.

0
Today / 09:31
|
784

Jefferies Initiates X-Energy Stock with Hold Rating

Jefferies initiates X-Energy stock coverage with a Hold rating and $28 target. Learn about risks and recent performance.

0
Today / 09:11
|
441

UBS Upgrades Jazz Pharma on Ziihera Potential

UBS upgrades Jazz Pharmaceuticals to Buy with a $307 target on Ziihera potential. Bond.az provides detailed analysis and stock insights.

0
...